Hereditary Angioedema (HAE) - Pipeline Review, H1 2017

  • ID: 4318745
  • Report
  • 90 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • CSL Ltd
  • iBio Inc
  • Ionis Pharmaceuticals Inc
  • Pharming Group NV
  • Shire Plc
  • MORE
Hereditary Angioedema (HAE) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2017, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline landscape.

Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 4, 10 and 2 respectively.

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • CSL Ltd
  • iBio Inc
  • Ionis Pharmaceuticals Inc
  • Pharming Group NV
  • Shire Plc
  • MORE
  1. Introduction
  2. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview
  3. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development
  13. ActiveSite Pharmaceuticals Inc
  14. Adverum Biotechnologies Inc
  15. Arrowhead Pharmaceuticals Inc
  16. BioCryst Pharmaceuticals Inc
  17. Cevec Pharmaceuticals GmbH
  18. CSL Ltd
  19. Global Blood Therapeutics Inc
  20. iBio Inc
  21. Ionis Pharmaceuticals Inc
  22. Kalvista Pharmaceuticals Inc
  23. Pharming Group NV
  24. ProMetic Life Sciences Inc
  25. Shire Plc
  26. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drug Profiles
  27. ADVM-053 - Drug Profile
  28. Product Description
  29. Mechanism Of Action
  30. R&D Progress
  31. AROF-12 - Drug Profile
  32. Product Description
  33. Mechanism Of Action
  34. R&D Progress
  35. ATN-035 - Drug Profile
  36. Product Description
  37. Mechanism Of Action
  38. R&D Progress
  39. ATN-249 - Drug Profile
  40. Product Description
  41. Mechanism Of Action
  42. R&D Progress
  43. BCX-7353 - Drug Profile
  44. Product Description
  45. Mechanism Of Action
  46. R&D Progress
  47. C1 esterase inhibitor (human) - Drug Profile
  48. Product Description
  49. Mechanism Of Action
  50. R&D Progress
  51. C1 esterase inhibitor (human) - Drug Profile
  52. Product Description
  53. Mechanism Of Action
  54. R&D Progress
  55. C1 esterase inhibitor (human) - Drug Profile
  56. Product Description
  57. Mechanism Of Action
  58. R&D Progress
  59. C1 esterase inhibitor (recombinant) - Drug Profile
  60. Product Description
  61. Mechanism Of Action
  62. R&D Progress
  63. C1 esterase inhibitor (recombinant) - Drug Profile
  64. Product Description
  65. Mechanism Of Action
  66. R&D Progress
  67. CSL-312 - Drug Profile
  68. Product Description
  69. Mechanism Of Action
  70. R&D Progress
  71. GBT-18713 - Drug Profile
  72. Product Description
  73. Mechanism Of Action
  74. R&D Progress
  75. icatibant acetate - Drug Profile
  76. Product Description
  77. Mechanism Of Action
  78. R&D Progress
  79. IONIS-PKKLRx - Drug Profile
  80. Product Description
  81. Mechanism Of Action
  82. R&D Progress
  83. IONIS-PKKRx - Drug Profile
  84. Product Description
  85. Mechanism Of Action
  86. R&D Progress
  87. KVD-818 - Drug Profile
  88. Product Description
  89. Mechanism Of Action
  90. R&D Progress
  91. lanadelumab - Drug Profile
  92. Product Description
  93. Mechanism Of Action
  94. R&D Progress
  95. Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema - Drug Profile
  96. Product Description
  97. Mechanism Of Action
  98. R&D Progress
  99. SHP-623 - Drug Profile
  100. Product Description
  101. Mechanism Of Action
  102. R&D Progress
  103. Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
  104. Product Description
  105. Mechanism Of Action
  106. R&D Progress
  107. Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
  108. Product Description
  109. Mechanism Of Action
  110. R&D Progress
  111. Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
  112. Product Description
  113. Mechanism Of Action
  114. R&D Progress
  115. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects
  116. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products
  117. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Product Development Milestones
  118. Featured News & Press Releases
  119. May 25, 2017: BioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial
  120. May 22, 2017: Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop
  121. May 18, 2017: Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial
  122. Apr 12, 2017: BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks
  123. Apr 04, 2017: New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients
  124. Mar 22, 2017: NEJM Publishes Pivotal Data on Preventing HAE Attacks
  125. Mar 16, 2017: Shire Receives European Approval for Label Extension of CINRYZE to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Pediatric Patients with HAE
  126. Mar 06, 2017: Attune Pharmaceuticals Announces Pre-Clinical Data for ATN-249, An Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at AAAAI
  127. Mar 01, 2017: Attune Pharmaceuticals Announces Late-Breaking Poster Presentation of ATN-249, an Oral Kallikrein Inhibitor for the Treatment of HAE
  128. Feb 27, 2017: BioCryst Reports Positive Interim Results from its APeX-1 Trial
  129. Feb 23, 2017: New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for Hereditary Angioedema, a Rare Genetic Disease
  130. Jan 16, 2017: European Commission amends Marketing Authorisation for RUCONEST to include self-administration
  131. Dec 15, 2016: CHMP Adopts Extension To Existing Therapeutic Indication For Cinryze
  132. Dec 01, 2016: CSL Commits to New Phase I Clinical Trials of CSL312 in Australia
  133. Nov 14, 2016: Pharming Announces the Presentation of the Results of the RUCONEST Phase II study for Prophylaxis of Hereditary Angioedema Attacks
  134. Appendix
  135. Methodology
  136. Coverage
  137. Secondary Research
  138. Primary Research
  139. Expert Panel Validation
  140. Contact Us
  141. Disclaimer
List of Tables
  1. Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1
  2. Number of Products under Development by Companies, H1
  3. Products under Development by Companies, H1
  4. Products under Development by Companies, H1 2017 (Contd..1), H1
  5. Number of Products by Stage and Target, H1
  6. Number of Products by Stage and Mechanism of Action, H1
  7. Number of Products by Stage and Route of Administration, H1
  8. Number of Products by Stage and Molecule Type, H1
  9. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ActiveSite Pharmaceuticals Inc, H1
  10. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Adverum Biotechnologies Inc, H1
  11. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Arrowhead Pharmaceuticals Inc, H1
  12. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by BioCryst Pharmaceuticals Inc, H1
  13. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Cevec Pharmaceuticals GmbH, H1
  14. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CSL Ltd, H1
  15. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Global Blood Therapeutics Inc, H1
  16. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by iBio Inc, H1
  17. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ionis Pharmaceuticals Inc, H1
  18. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Kalvista Pharmaceuticals Inc, H1
  19. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharming Group NV, H1
  20. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ProMetic Life Sciences Inc, H1
  21. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Shire Plc, H1
  22. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects, H1
  23. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products, H1
List of Figures
  1. Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products by Targets, H1
  4. Number of Products by Stage and Targets, H1
  5. Number of Products by Mechanism of Actions, H1
  6. Number of Products by Stage and Mechanism of Actions, H1
  7. Number of Products by Routes of Administration, H1
  8. Number of Products by Stage and Routes of Administration, H1
  9. Number of Products by Molecule Types, H1
  10. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • ActiveSite Pharmaceuticals Inc
  • Adverum Biotechnologies Inc
  • Arrowhead Pharmaceuticals Inc
  • BioCryst Pharmaceuticals Inc
  • Cevec Pharmaceuticals GmbH
  • CSL Ltd
  • Global Blood Therapeutics Inc
  • iBio Inc
  • Ionis Pharmaceuticals Inc
  • Kalvista Pharmaceuticals Inc
  • Pharming Group NV
  • ProMetic Life Sciences Inc
  • Shire Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll